1426572-71-5

Basic information

• Product Name: (2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide
• CAS NO: 1426572-71-5
• Molecular Weight: 332.359
• Mol File: 1426572-71-5.mol

Chemical Properties

• CAS DataBase Reference: (2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide(1426572-71-5)
• EPA Substance Registry System: (2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide(1426572-71-5)

Safety Data

• Hazardous Substances Data: 1426572-71-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide is used as a potential enzyme inhibitor for pharmaceutical research, as its unique structure allows it to target specific enzymes involved in various diseases.
Used in Drug Discovery:
In the field of drug discovery, (2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide is used as a starting point for the development of new enzyme inhibitors, which can be further optimized and modified to improve their efficacy and selectivity.
Used in Laboratory Experiments:
(2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide is used in laboratory experiments to study its biological activity, mechanism of action, and potential applications in treating various diseases.
Used in Clinical Studies:
(2S,5R)-N’-acetyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carbohydrazide is also used in clinical studies to evaluate its safety, efficacy, and potential side effects, which can help in the development of new drugs and therapies for various medical conditions.

Upstream product

• 1174020-25-7 (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 
• 1068-57-1 acetic acid hydrazide 
• 208519-98-6 (S)-ethyl 2-(((tert-butoxy)carbonyl)amino)-6-diazo-5-oxohexanoate 
• 1416134-58-1 ethyl (S)-2-((tert-butoxycarbonyl)amino)-6-(dimethyl(oxo)-λ⁶-sulfanylidene)-5-oxohexanoate 
• 77925-80-5 N-(2-Nitrophenylsulfonyl)-O-(phenylmethyl)hydroxylamine 
• 1463501-45-2 (2S,5R)-1-tert-butyl 2-ethyl 5-(N-(benzyloxy)-(2-nitrophenyl)sulfonamido)piperidine-1,2-dicarboxylate 
• 1463501-46-3 (2S,5R)-5-(benzyloxyamino)piperidin-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 1416134-47-8 (2S,5R)?5?[(benzyloxy)amino]piperidine?2?carboxylate 
• 1416134-63-8 (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octan-2-carboxylic acid ethyl ester 
• 64-19-7 acetic acid 
• 32159-21-0 Cbz-L-pGlu-OH 
• 81470-51-1 tert-butyl N-benzyloxycarbonyl-L-pyroglutamate 
• 147489-30-3 (2S)-5-oxopiperidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 169825-97-2 N-benzyloxycarbonyl-(2S,5S)-5-hydroxypipecolic acid tert-butyl ester 

Downstream Products

• 1426572-72-6 (2S,5R)-6-(benzyloxy)-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1,6-diaza-bicyclo[3.2.1]octan-7-one 

Relevant articles and documents

NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME

The currently available β-lactamase inhibitors are insufficient to inhibit the incessantly increasing β-lactamase, and novel β-lactamase inhibitors has been required today for the difficult treatment for bacterial infectious diseases caused by resistant bacteria which produce class C β-lactamase, extended-spectrum β-lactamase (ESBL) belonging to class A and D, or class A KPC-2 decomposing even carbapenem as a last resort for β-lactam antibiotic. A compound represented by the the formula (I), preparation process of the same, β-lactamase inhibitors and method for treating bacterial infectious diseases are provided.

NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

A compound of formula (I), wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

BETA-LACTAMASE INHIBITORS

Aryl substituted diazabicyclooctanes (DBO) compounds that inhibit β-lactamases of class A, class C or class D and potentiate β-lactam antibiotics are disclosed. In particular, this disclosure provides DBO compounds that, when used in the disclosed Synergy MIC Assay with a β-lactam antibiotic at a fixed concentration have an MIC of 8 μg/mL or less against one or more isogenic β-lactamase expressing bacterial strains.

NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS

A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

1,6- DIAZABICYCLO [3,2,1] OCTAN- 7 - ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS

Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.